Abstract PR299: Randomized Controlled Trail of Stellate Ganglion Block Combined with Brainwave Traction Technology for Chronic Migraine with Migraine-Associated Insomnia

Background & Objectives: Migraine is a highly disabling primary headache disorder. Among these, chronic migraine (CM) is the most serious branch. CM is frequently triggered by insomnia and a great proportion of CM is concomitant with insomnia[1].Recommended treatment for CM and for insomnia are neither readily inaccessible nor bearing some unacceptable side effects[2-3].Our aim of this trail is to evaluate the treatment effect of stellate ganglion block(SGB) and brainwave tract treatment (BTT) in patients with CM and migraine related insomnia. Materials & Methods: A monocentric, randomized, controlled, single-blind study was conducted. Patients were randomized to receive totally drug (group O) or drug with SGB(group A) or drug with SGB and BTT(group B) for 3 months. Baseline and after 1 month and 3 months of each treatment values for the number of headache days with moderate or severe intensity per month and number of migraine days per month and number of migraine episodes per month were determined on the basis of patient reporting and medical history. Furthermore, The Headache Impact Test (HIT-6) and the Migraine Disability Assessment (MIDAS) questionnaires were used to assess headache-related disability. Data from brainwave traction treatment is generated automatically and it contains the health of brain and the ability of brain. All treatment-related adverse events (AEs) were recorded. Results: Of 40 randomized patients, 36 finished the study. Patients in group A and group B had a significantly reduction in headache days with moderate or severe intensity per month and number of migraine days per month and number of migraine episodes per month than patients in group O. Patients in group O has transient reduction in in those indicators at 1 month but not 3 month. However, there was no significant different in those indicators between group A and group B.HIT-6 and MIDAS scores were significantly improved in group A and group B, without group differences, but not improved in group O. PSQI score in three groups were significantly reduced without differences between groups. There were no serious treatment-related adverse events. Conclusion: Preventive drugs were not as effective as SGB in treating patients with CM and migraine related insomnia in this trail. BTT was not effective than expected, perhaps in that the sample is small or the instrument for BTT should be adjusted. References: 1. Hamelsky, S.W. and R.B. Lipton, Psychiatric comorbidity of migraine. Headache, 2006. 46(9): p. 1327-33. 2. Szok, D., et al., Treatment of Chronic Migraine with OnabotulinumtoxinA: Mode of Action, Efficacy and Safety. Toxins (Basel), 2015. 7(7): p. 2659-73. 3. Schaefer, S.M., C.H. Gottschalk, and B. Jabbari, Treatment of Chronic Migraine with Focus on Botulinum Neurotoxins. Toxins (Basel), 2015. 7(7): p. 2615-28. Disclosure of Interest: None declared